Organon & Co. (OGN)

NYSE: OGN · IEX Real-Time Price · USD
22.38
-0.01 (-0.04%)
At close: Mar 21, 2023, 4:04 PM
22.29
-0.09 (-0.40%)
After-hours: Mar 21, 2023, 4:18 PM EDT
-0.04%
Market Cap 5.69B
Revenue (ttm) 6.17B
Net Income (ttm) 917.00M
Shares Out 254.38M
EPS (ttm) 3.59
PE Ratio 6.24
Forward PE 5.03
Dividend $1.12 (5.00%)
Ex-Dividend Date Feb 24, 2023
Volume 2,031,772
Open 22.59
Previous Close 22.39
Day's Range 22.24 - 22.78
52-Week Range 21.11 - 39.09
Beta n/a
Analysts Buy
Price Target 33.53 (+49.82%)
Earnings Date May 4, 2023

About OGN

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of seve... [Read more]

Sector Healthcare
Founded 1923
Employees 10,000
Stock Exchange NYSE
Ticker Symbol OGN
Full Company Profile

Financial Performance

In 2022, Organon & Co.'s revenue was $6.17 billion, a decrease of -2.06% compared to the previous year's $6.30 billion. Earnings were $917.00 million, a decrease of -32.12%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for OGN stock is "Buy." The 12-month stock price forecast is $33.53, which is an increase of 49.82% from the latest price.

Price Target
$33.53
(49.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. ("Organon" or the "Company") (NYSE:  OGN).  Such investors are advised to contac...

1 week ago - PRNewsWire

Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist

Building on Organon's Prior FP2030 Commitment, the Company Announces $30 Million in New Funding to Fuel Global Action and Community-Driven Solutions Needed by the 121 Million Women and Girls Who Exper...

2 weeks ago - Business Wire

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

Dear Investor:

Other symbols: ETFMSTAROTEVAVTRS
3 weeks ago - GuruFocus

Organon (OGN) Q4 Earnings and Revenues Miss Estimates

Organon (OGN) delivered earnings and revenue surprises of -4.71% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022. "We enter 2023 with momentum, building off the signifi...

1 month ago - Business Wire

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women's healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the c...

1 month ago - Business Wire

Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women's healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an in...

2 months ago - Business Wire

Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a firesi...

3 months ago - Business Wire

Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women's healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will c...

3 months ago - Business Wire

Organon To Present at the Piper Sandler 34th Annual Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a firesi...

4 months ago - Business Wire

Organon (OGN) Q3 Earnings and Revenues Top Estimates

Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Organon Reports Results for the Third Quarter Ended September 30, 2022

JERSEY CITY, N.J.

4 months ago - Business Wire

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Jim Cramer gives his take on Organon

Cramer on Tuesday explained his thoughts on pharmaceutical firm Organon.

5 months ago - CNBC Television

Drugmaker stocks lead sector with healthy dividends

CNBC's Bertha Coombs reports on health care stocks.

Other symbols: ABBVCVSGILDVTRS
6 months ago - CNBC Television

Health care stocks with dividend yields to weather through market turmoil

The healthcare sector is an investor favorite in a defensive market. CNBC's Bertha Coombs joins 'Squawk Box' to break down some players with the best dividend yields.

Other symbols: ABBVCVSGILDVTRS
6 months ago - CNBC Television

Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)

INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE)--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)

7 months ago - Business Wire

New Strong Sell Stocks for August 8th

COWN, AUD, and OGN have been added to the Zacks Rank #5 (Strong Sell) List on August 8, 2022.

Other symbols: AUD
8 months ago - Zacks Investment Research

Organon (OGN) Surpasses Q2 Earnings and Revenue Estimates

Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Organon Reports Results for the Second Quarter Ended June 30, 2022

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports results for the second quarter ended June 30, 2022

8 months ago - Business Wire

Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #contraception--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidat...

8 months ago - Business Wire

Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #organon--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company's webcast and call scheduled for 8:30 a.m. EDT.

8 months ago - Business Wire